国证国际港股晨报-20250804

Core Viewpoints - The employment data has severely impacted market confidence, leading to declines in major indices such as the Hang Seng Index, which fell by 1.07% [2] - The market is experiencing a significant sell-off, with a notable increase in short-selling activity, indicating a bearish sentiment among investors [2][4] Company Overview - The specific company under review, Zhonghui Biotech, was established in 2015 and focuses on the development of innovative vaccines, including a quadrivalent influenza vaccine and a freeze-dried rabies vaccine [10] - The quadrivalent influenza vaccine was launched in May 2023, marking it as the first and only approved vaccine of its kind in China [10] - The company is currently in a loss-making position, with projected revenues of 52.2 million and 259.6 million for 2023 and 2024 respectively, while total losses are expected to reach 424.7 million and 258.7 million for the same years [10] Industry Status and Outlook - The Chinese human vaccine market is projected to grow significantly, from 53.5 billion in 2019 to 96.1 billion by 2024, with a CAGR of 12.4% [11] - By 2033, the market is expected to reach 331.9 billion, driven by technological advancements, increased public awareness of vaccination, and supportive preventive healthcare policies [11] Advantages and Opportunities - The company has the potential to address unmet needs in the high-quality vaccine market with its quadrivalent influenza vaccine, which offers higher safety and better immune response [12] - A leading R&D technology platform supports the development of its vaccine pipeline, which includes 11 additional vaccines currently in research [12] Fundraising and Use of Proceeds - The IPO is set to raise funds with approximately 63.6% allocated for the development and registration of core products, while 18.1% will be used for other vaccine developments [16] - The remaining funds will enhance production capabilities and support operational costs [16] Investment Recommendation - The IPO price range is set between 12.9 and 15.5 HKD, with a post-IPO market capitalization estimated at 50.75 to 60.98 billion HKD [17] - The valuation appears high when compared to peers, with a projected PS ratio of 17.9 to 21.6 for 2024 [17]